185 related articles for article (PubMed ID: 9892624)
1. Migration kinetics and final destination of type 1 and type 2 CD8 effector cells predict protection against pulmonary virus infection.
Cerwenka A; Morgan TM; Harmsen AG; Dutton RW
J Exp Med; 1999 Jan; 189(2):423-34. PubMed ID: 9892624
[TBL] [Abstract][Full Text] [Related]
2. Naive, effector, and memory CD8 T cells in protection against pulmonary influenza virus infection: homing properties rather than initial frequencies are crucial.
Cerwenka A; Morgan TM; Dutton RW
J Immunol; 1999 Nov; 163(10):5535-43. PubMed ID: 10553081
[TBL] [Abstract][Full Text] [Related]
3. Production of interferon-gamma by influenza hemagglutinin-specific CD8 effector T cells influences the development of pulmonary immunopathology.
Wiley JA; Cerwenka A; Harkema JR; Dutton RW; Harmsen AG
Am J Pathol; 2001 Jan; 158(1):119-30. PubMed ID: 11141485
[TBL] [Abstract][Full Text] [Related]
4. Tumor-specific Tc1, but not Tc2, cells deliver protective antitumor immunity.
Kemp RA; Ronchese F
J Immunol; 2001 Dec; 167(11):6497-502. PubMed ID: 11714817
[TBL] [Abstract][Full Text] [Related]
5. In vivo persistence of CD8 polarized T cell subsets producing type 1 or type 2 cytokines.
Cerwenka A; Carter LL; Reome JB; Swain SL; Dutton RW
J Immunol; 1998 Jul; 161(1):97-105. PubMed ID: 9647212
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic effects of tumor-reactive type 1 and type 2 CD8+ T cell subpopulations in established pulmonary metastases.
Dobrzanski MJ; Reome JB; Dutton RW
J Immunol; 1999 Jun; 162(11):6671-80. PubMed ID: 10352285
[TBL] [Abstract][Full Text] [Related]
7. Relative diabetogenic properties of islet-specific Tc1 and Tc2 cells in immunocompetent hosts.
Vizler C; Bercovici N; Heurtier A; Pardigon N; Goude K; Bailly K; Combadière C; Liblau RS
J Immunol; 2000 Dec; 165(11):6314-21. PubMed ID: 11086068
[TBL] [Abstract][Full Text] [Related]
8. The role of adoptively transferred CD8 T cells and host cells in the control of the growth of the EG7 thymoma: factors that determine the relative effectiveness and homing properties of Tc1 and Tc2 effectors.
Helmich BK; Dutton RW
J Immunol; 2001 Jun; 166(11):6500-8. PubMed ID: 11359800
[TBL] [Abstract][Full Text] [Related]
9. Cellular mechanisms involved in protection against influenza virus infection in transgenic mice expressing a TCR receptor specific for class II hemagglutinin peptide in CD4+ and CD8+ T cells.
Bot A; Casares S; Bot S; von Boehmer H; Bona C
J Immunol; 1998 May; 160(9):4500-7. PubMed ID: 9574556
[TBL] [Abstract][Full Text] [Related]
10. Effector cell-derived lymphotoxin alpha and Fas ligand, but not perforin, promote Tc1 and Tc2 effector cell-mediated tumor therapy in established pulmonary metastases.
Dobrzanski MJ; Reome JB; Hollenbaugh JA; Hylind JC; Dutton RW
Cancer Res; 2004 Jan; 64(1):406-14. PubMed ID: 14729652
[TBL] [Abstract][Full Text] [Related]
11. CD8-mediated type 1 antitumor responses selectively modulate endogenous differentiated and nondifferentiated T cell localization, activation, and function in progressive breast cancer.
Dobrzanski MJ; Reome JB; Hylind JC; Rewers-Felkins KA
J Immunol; 2006 Dec; 177(11):8191-201. PubMed ID: 17114496
[TBL] [Abstract][Full Text] [Related]
12. In vitro generation of allospecific human CD8+ T cells of Tc1 and Tc2 phenotype.
Halverson DC; Schwartz GN; Carter C; Gress RE; Fowler DH
Blood; 1997 Sep; 90(5):2089-96. PubMed ID: 9292548
[TBL] [Abstract][Full Text] [Related]
13. Type 1 CD8+ T cells are superior to type 2 CD8+ T cells in tumor immunotherapy due to their efficient cytotoxicity, prolonged survival and type 1 immune modulation.
Ye Z; Tang C; Xu S; Zhang B; Zhang X; Moyana T; Yang J; Xiang J
Cell Mol Immunol; 2007 Aug; 4(4):277-85. PubMed ID: 17764618
[TBL] [Abstract][Full Text] [Related]
14. Rapid clearance of herpes simplex virus type 2 by CD8+ T cells requires high level expression of effector T cell functions.
Nelson MH; Bird MD; Chu CF; Johnson AJ; Friedrich BM; Allman WR; Milligan GN
J Reprod Immunol; 2011 Apr; 89(1):10-7. PubMed ID: 21444117
[TBL] [Abstract][Full Text] [Related]
15. CD8Tc1 and Tc2 cells secrete distinct cytokine patterns in vitro and in vivo but induce similar inflammatory reactions.
Li L; Sad S; Kägi D; Mosmann TR
J Immunol; 1997 May; 158(9):4152-61. PubMed ID: 9126975
[TBL] [Abstract][Full Text] [Related]
16. Committed memory effector type 2 cytotoxic T (Tc2) cells are ineffective in protective anti-tumor immunity.
Do JS; Choi YH; Shin SH; Yi HK; Hwang PH; Nam SY
Immunol Lett; 2004 Aug; 95(1):77-84. PubMed ID: 15325801
[TBL] [Abstract][Full Text] [Related]
17. CD8(+) T cells secreting type 2 lymphokines are defective in protection against viral infection.
Wirth S; van den Broek M; Frossard CP; Hügin AW; Leblond I; Pircher H; Hauser C
Cell Immunol; 2000 May; 202(1):13-22. PubMed ID: 10873302
[TBL] [Abstract][Full Text] [Related]
18. Allospecific CD8+ Tc1 and Tc2 populations in graft-versus-leukemia effect and graft-versus-host disease.
Fowler DH; Breglio J; Nagel G; Eckhaus MA; Gress RE
J Immunol; 1996 Dec; 157(11):4811-21. PubMed ID: 8943383
[TBL] [Abstract][Full Text] [Related]
19. Virus-specific CD8(+) T cells with type 1 or type 2 cytokine profile are related to different disease activity in chronic hepatitis C virus infection.
Prezzi C; Casciaro MA; Francavilla V; Schiaffella E; Finocchi L; Chircu LV; Bruno G; Sette A; Abrignani S; Barnaba V
Eur J Immunol; 2001 Mar; 31(3):894-906. PubMed ID: 11241295
[TBL] [Abstract][Full Text] [Related]
20. CD8(+) T cells with distinct cytokine-producing features and low cytotoxic activity in eosinophilic and non-eosinophilic chronic rhinosinusitis with nasal polyps.
Ma J; Shi LL; Deng YK; Wang H; Cao PP; Long XB; Zhang XH; Liu Y; Zeng M; Liu Z
Clin Exp Allergy; 2016 Sep; 46(9):1162-75. PubMed ID: 27176491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
